An honor and pleasure being part of this amazing (and thought provoking) work lead by Martina Fiumara & Samuele Ferrari, Congrats!!! Must read for any #GeneEditors out there!

Fondazione Telethon prima charity al mondo responsabile della produzione e distribuzione di un farmaco. telethon.it/storie-e-news/…

🔥More gems from our nature paper 🔍intracellular carboplatin increasingly accumulate during therapy, expecially in macrophages 🔍T cells in direct contact with cancer cells were functionally distinct:⬆️activation markers TOX, PD-1, OX40 and⬆️proliferating See also thread👇👇

🧵 1/10 🔬 Out on European Journal Of Cancer “Pan-cancer analysis of antibody-drug conjugate targets and putative predictors of treatment response” DOI:doi.org/10.1016/j.ejca… If you want to know more about ADCs 👇👇👇

Our work has been published in Cancer Cell Thanks everyone! Ospedale San Raffaele Fondazione AIRC per la ricerca sul cancro #GeneTherapy #Immunotherapy In vivo macrophage engineering reshapes the tumor microenvironment leading to eradication of liver metastases: Cancer Cell cell.com/cancer-cell/fu…

Lo studio sperimentale dimostra l’efficacia di una nuova strategia genica in grado di riattivare le risposte immunitarie delle cellule del fegato contro le metastasi epatiche. hsr.it/news/2023/otto…

💥DO NOT MISS our Metanalysis on #Perioperative ICI+CT in early #NSCLC • #Neoadjuvant ICI+CT vs CT: ⬆️pCR, MPR, EFS, OS, R0 • ICI+CT ⬆️ pCR in PD-L1 neg • If pCR ➡️ 99% EFS 1 y • Neoadj/periop ICI+CT works better in stage III • Neoadj 🟰 perioperative in OS

Base and prime editors induce double-strand breaks, deletions and translocations in hematopoietic cells go.nature.com/3EsAAoe

Proud to see our new work on advanced #HCC out in International Journal of Cancer❗ 🚨New px/predictive score of response to #atezbev 🌍Large #realworld population (Europe&Asia) 🔀May help #decisionmaking in I line 🙏andrea casadei gardini Margherita Rimini & co-authors ⬇️Give a look⬇️ onlinelibrary.wiley.com/share/author/C…

#Phacilitate Lifetime Achievement Award winner Dr Luigi Naldini describes his career-defining journey working to develop and curate #LentiviralVectors for safer and more effective #GeneTherapy opportunities. Watch the Full Interview Here - ow.ly/RYsA50QnJ85 #ATW

1/4 📢Calling all T-Dxd prescribers!💉 Out now in Frontiers - Oncology our real-world study on the impact of antiemetic prophylaxis in patients treated with T-DXd highlighted the efficacy of the three-drug regimen (with NK1RA) doi.org/10.3389/fonc.2… Luca Licata, MD Giampaolo Bianchini 🧵👇🏻👇🏻

In Annals of Oncology, Biagio Ricciuti, MD PhD & coll. review challenges & opportunities for TMB & immunotherapy: 🔹Technical limitations 🔹Spatial & temporal heterogeneity 🔹Co-occuring genomic and non-genomic factors 🔹Strategies to improve predictivity annalsofoncology.org/article/S0923-… 2/2

Excited to share our latest publication on JAMA Network Open : "Completion rate and positive results reporting among immunotherapy trials in breast cancer, 2004-2023.” #BreastCancerResearch OncoAlert Ospedale San Raffaele 👇Check out some key insights below

Quality > Quantity.

🔥Impressed by PATINA trial results? 👉 the longest mPFS ever in breast cancer (44 mths) Unexpected? Not really - Our study (👇👇) explain the biological rational - Supportive clinical trials (NA-PHER2, PERTAIN) ❗️CLEOPATRA trial did not allow ET maintenance SABCS

🚨 What if a single DNA typo could inflame the body and outcompete healthy blood cells? 🧬 This happens in #VEXAS syndrome. In our paper out today in Nature Medicine we show how. 📖 Here: rb.gy/300drs 👇 A story of inflammation, clonal warfare and #CRISPR editing 🧵

🆕Time to tailor chemo-IO in resected NSCLC. Reconstructed individual pts data show NEOAD= PERIOP in pCR, MPR, non-MPR. PERIOP performs well in pure-MPR (1-10%RVT). pCR or no-MPR deserve descalation or escalation strategies. Antonio Nuccio giuseppe viscardi Fabio Salomone JNCI

🚨 New publication alert! andrea casadei gardini We investigated how early bevacizumab dose/time modifications (eBEVmod) impact the efficacy of Atezolizumab + Bevacizumab in advanced hepatocellular carcinoma (aHCC) treatment in a real-world setting. 📄 Read: authors.elsevier.com/sd/article/S29… 👇

Want to dive into patterns, biomarkers and strategies to overcome primary and acquired resistance to immunotherapy in lung cancer? Check out our review just published on NatureRevClinOncol. A master piece from Martin Reck Fabrice Barlesi and many other kols! nature.com/articles/s4157…

I owe a huge thank you to @GiampaoloBianch and all the Milan OSR team for their constant guidance and inspiration. Honoured to join Cambridge University as a ESMO - Eur. Oncology Research Fellow, carrying forward our shared passion for patient-centred science 🔬💙